Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 1
2006 1
2007 1
2008 2
2009 4
2010 1
2011 1
2012 1
2013 2
2014 5
2015 5
2016 5
2017 7
2018 8
2019 5
2020 3
2021 1
2022 3
2023 6
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

58 results

Results by year

Filters applied: . Clear all
Page 1
Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study.
Karasik A, Lanzinger S, Chia-Hui Tan E, Yabe D, Kim DJ, Sheu WH, Melzer-Cohen C, Holl RW, Ha KH, Khunti K, Zaccardi F, Subramanian A, Nirantharakumar K, Nyström T, Niskanen L, Linnemann Jensen M, Hoti F, Klement R, Déruaz-Luyet A, Kyaw MH, Koeneman L, Vistisen D, Carstensen B, Halvorsen S, Langslet G, Fazeli Farsani S, Patorno E, Núñez J; EMPRISE Europe and Asia Study Group. Karasik A, et al. Among authors: hoti f. Diabetes Metab. 2023 Mar;49(2):101418. doi: 10.1016/j.diabet.2022.101418. Epub 2023 Jan 3. Diabetes Metab. 2023. PMID: 36608816 Free article.
Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia.
Vistisen D, Carstensen B, Elisabetta P, Lanzinger S, Tan EC, Yabe D, Kim DJ, Sheu WH, Melzer-Cohen C, Holl RW, Núñez J, Ha KH, Halvorsen S, Langslet G, Karasik A, Nyström T, Niskanen L, Guleria S, Klement R, Carrasco M, Foersch J, Shay C, Koeneman L, Hoti F, Farsani SF, Khunti K, Zaccardi F, Subramanian A, Nirantharakumar K; EMPRISE EU; East Asia Study Group. Vistisen D, et al. Among authors: hoti f. Cardiovasc Diabetol. 2023 Aug 31;22(1):233. doi: 10.1186/s12933-023-01963-9. Cardiovasc Diabetol. 2023. PMID: 37653496 Free PMC article.
Prenatal exposure to pregabalin, birth outcomes and neurodevelopment - a population-based cohort study in four Nordic countries.
Dudukina E, Szépligeti SK, Karlsson P, Asomaning K, Daltveit AK, Hakkarainen K, Hoti F, Kieler H, Lunde A, Odsbu I, Rantanen M, Reutfors J, Saarelainen L, Ehrenstein V, Toft G. Dudukina E, et al. Among authors: hoti f. Drug Saf. 2023 Jul;46(7):661-675. doi: 10.1007/s40264-023-01307-2. Epub 2023 Apr 26. Drug Saf. 2023. PMID: 37099261 Free PMC article.
Management of COVID-19 Cases in Kosova.
Ahmeti S, Keske Ş, Namani-Avdiu S, Ajazaj-Berisha L, Vishaj A, Sadik I, Alimusaj M, Hoti F, Ahmeti H, Sait B, Çakar N, Ergönül Ö. Ahmeti S, et al. Among authors: hoti f. Infect Dis Clin Microbiol. 2022 Jun 13;4(2):144-147. doi: 10.36519/idcm.2022.125. eCollection 2022 Jun. Infect Dis Clin Microbiol. 2022. PMID: 38633341 Free PMC article. No abstract available.
Risk of cardiovascular events after an exacerbation of chronic obstructive pulmonary disease: results from the EXACOS-CV cohort study using the PHARMO Data Network in the Netherlands.
Swart KMA, Baak BN, Lemmens L, Penning-van Beest FJA, Bengtsson C, Lobier M, Hoti F, Vojinovic D, van Burk L, Rhodes K, Garbe E, Herings RMC, Nordon C, Simons SO. Swart KMA, et al. Among authors: hoti f. Respir Res. 2023 Nov 21;24(1):293. doi: 10.1186/s12931-023-02601-4. Respir Res. 2023. PMID: 37990197 Free PMC article.
Validation of safety outcomes in routinely collected data: Lessons learned from a multinational postapproval safety study.
Arena PJ, Huang K, Löfling L, Bahmanyar S, Mo J, Schachterle SE, Nunes AP, Smits E, Juuti R, Hoti F, Korhonen P, Adelborg K, Sundbøll J, Rasmussen TR, Løkke A, Ehrenstein V. Arena PJ, et al. Among authors: hoti f. Pharmacoepidemiol Drug Saf. 2023 May;32(5):592-596. doi: 10.1002/pds.5582. Epub 2022 Dec 29. Pharmacoepidemiol Drug Saf. 2023. PMID: 36495188 No abstract available.
Patients With COPD who Initiate Roflumilast in Sweden.
Khalid JM, Mushnikov V, Vattulainen P, Johansson G, Korhonen P, Hoti F. Khalid JM, et al. Among authors: hoti f. Value Health. 2014 Nov;17(7):A590. doi: 10.1016/j.jval.2014.08.2022. Epub 2014 Oct 26. Value Health. 2014. PMID: 27202016 Free article. No abstract available.
58 results